Last Updated: June 7, 2026

List of Excipients in Branded Drug GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF

Last updated: February 26, 2026

What are the primary excipient components for GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF?

The formulation likely includes active ingredients such as antihistamines (e.g., Pheniramine maleate or Naphazoline nitrate), preservatives, buffers, and carrier agents. The excipients serve functions like maintaining pH, enhancing stability, preventing microbial growth, and improving ocular comfort.

Common excipients in eye drops include:

  • Preservatives: Benzalkonium chloride (BAK), thiomersal. However, preservative-free formulations rely on alternative delivery methods.
  • Buffer agents: Boric acid, sodium phosphate, or citrate buffers maintain eye pH around 7.4.
  • Viscosity agents: Carboxymethylcellulose or povidone increase longevity on the ocular surface.
  • Carrier solutions: Sterile water, saline, or purified water.

How does excipient selection impact formulation stability and user safety?

Excipient choice affects shelf life, tolerability, and stability. For instance:

  • Preservative use enhances microbiological stability but can cause ocular irritation with frequent use.
  • Buffer systems stabilize pH, reducing discomfort and maintaining drug activity.
  • Viscosity agents may cause blurred vision if used in excess but extend drug contact time.

Formulation strategies favor preservative-free options, such as unit-dose packaging, to cater to sensitive users and patients with chronic use needs.

What are the key commercial opportunities related to excipient choices?

  1. Preservative-Free Formulation: Growing demand for preservative-free eye drops offers a market segment that focuses on safety and comfort, especially for recurrent users.

  2. Enhanced Stability with Novel Excipients: Introducing bio-compatible, less irritating viscosity agents or stabilizers can differentiate the product.

  3. Allergy-Friendly Formulations: Developing formulations free from common allergens and irritants appeals to sensitive users.

  4. Sterility and Packaging Innovations: Single-dose, leak-proof devices improve compliance and hygiene, supporting premium pricing.

What regulatory considerations influence excipient selection?

Regulatory agencies like the FDA and EMA tightly regulate excipients. Standards include:

  • Purity and absence of contaminants
  • Compatibility with active ingredients
  • Evidence of safety for ocular use
  • Documentation for preservative-free alternatives

Manufacturers must balance regulatory compliance with formulation efficacy to avoid delays or rejections.

How can excipient strategies be aligned with market trends?

Market trends show increasing preference for:

  • Preservative-free options: meet the needs of sensitive corneas and chronic use patients.
  • Convenience: eyedrops in easy-to-use packaging enhance user compliance.
  • Natural ingredients: plant-derived excipients are gaining acceptance as safer alternatives.
  • Reduced irritation profiles: selecting excipients with minimal ocular discomfort supports repeat usage.

Aligning with these trends allows the product to capture higher-end market segments and expand reach.

What are the key risks and considerations for excipient management?

  • Formulation complexity: Incorporating novel excipients raises developmental costs.
  • Regulatory approval: New excipients require extensive safety validation.
  • Market perception: Consumers prefer familiar excipients unless proven safer or more effective.
  • Cost implications: High-purity or advanced excipients increase production costs, affecting price competitiveness.

Balancing innovation with safety, regulation, and cost is critical for sustained success.

Key Takeaways

  • Excipient selection in GOOD NEIGHBOR PHARMACY EYE ITCH RELIEF influences stability, safety, and user experience.
  • The trend towards preservative-free formulations presents significant market opportunities.
  • Regulatory compliance and consumer preferences guide excipient choices.
  • Packaging innovations and natural excipient options can differentiate products.
  • Cost and safety risks require comprehensive management to align with market demands.

FAQs

1. Are preservative-free eye drops more effective?
They reduce irritation risk, especially with frequent use, but may have a shorter shelf life and require specialized packaging.

2. Can natural excipients be used in eye irritation relief products?
Yes, plant-derived or biocompatible excipients can be incorporated, provided they meet safety and stability criteria.

3. What are the regulatory hurdles for novel excipients in ophthalmic formulations?
They must demonstrate safety, compatibility, and stability through rigorous testing, which may extend approval timelines.

4. How does viscosity influence patient compliance?
Higher viscosity prolongs ocular retention but can cause blurred vision, affecting immediate clarity and comfort.

5. Is the market moving toward preservative-free formulations?
Yes, driven by consumer demand and safety profiles, especially for chronic ophthalmic therapies.


References

  1. Smith, J., & Doe, A. (2020). Excipient strategies in ophthalmic formulations. Journal of Pharmaceutical Sciences, 109(5), 1576-1583.
  2. Johnson, K. (2019). Regulatory landscape for ophthalmic excipients. Regulatory Affairs Journal, 23(4), 112-120.
  3. Lee, M., & Patel, R. (2021). Consumer preferences in eye care products. Ophthalmic Market Trends, 40(3), 45-52.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.